Trade Helius Medical Technologies, Inc. - HSDT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.2508 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.02 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Helius Medical Technologies Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 9.0196 |
| Open* | 8.7996 |
| 1-Year Change* | 2929.12% |
| Day's Range* | 8.7996 - 9.3296 |
| 52 wk Range | 5.69-29.50 |
| Average Volume (10 days) | 2.19M |
| Average Volume (3 months) | 7.67M |
| Market Cap | 4.55M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 565.97K |
| Revenue | 787.00K |
| EPS | -120.55 |
| Dividend (Yield %) | N/A |
| Beta | 1.26 |
| Next Earnings Date | Nov 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 28, 2023 | 9.0196 | 0.4600 | 5.37% | 8.5596 | 9.1796 | 8.5596 |
| Sep 27, 2023 | 8.7196 | 0.8800 | 11.23% | 7.8396 | 8.9596 | 7.8396 |
| Sep 26, 2023 | 7.9596 | 0.3100 | 4.05% | 7.6496 | 7.9996 | 7.6496 |
| Sep 25, 2023 | 7.6396 | -0.5100 | -6.26% | 8.1496 | 8.2896 | 7.5496 |
| Sep 22, 2023 | 8.1796 | -0.3000 | -3.54% | 8.4796 | 10.8996 | 8.1796 |
| Sep 21, 2023 | 8.5696 | -0.1300 | -1.49% | 8.6996 | 8.8896 | 8.3996 |
| Sep 20, 2023 | 8.4496 | 0.2000 | 2.42% | 8.2496 | 8.8396 | 8.2496 |
| Sep 19, 2023 | 8.4596 | -0.2400 | -2.76% | 8.6996 | 8.8796 | 8.1596 |
| Sep 18, 2023 | 8.7196 | 0.4200 | 5.06% | 8.2996 | 8.7596 | 8.2996 |
| Sep 15, 2023 | 8.2996 | 0.0500 | 0.61% | 8.2496 | 8.4496 | 7.9996 |
| Sep 14, 2023 | 8.5096 | 0.3100 | 3.78% | 8.1996 | 8.7496 | 8.1996 |
| Sep 13, 2023 | 8.3496 | 0.3500 | 4.38% | 7.9996 | 8.4496 | 7.9996 |
| Sep 12, 2023 | 8.2696 | -0.5200 | -5.92% | 8.7896 | 8.7896 | 8.1096 |
| Sep 11, 2023 | 8.9996 | -0.8000 | -8.16% | 9.7996 | 10.3496 | 8.6196 |
| Sep 8, 2023 | 9.4330 | 1.5900 | 20.27% | 7.8430 | 10.9230 | 7.8430 |
| Sep 7, 2023 | 7.8530 | -0.1400 | -1.75% | 7.9930 | 8.6230 | 7.5030 |
| Sep 6, 2023 | 8.8930 | -0.2800 | -3.05% | 9.1730 | 9.3630 | 7.5930 |
| Sep 5, 2023 | 9.8930 | -2.2800 | -18.73% | 12.1730 | 12.5830 | 9.6030 |
| Sep 1, 2023 | 7.3630 | 1.0700 | 17.00% | 6.2930 | 7.8730 | 6.2830 |
| Aug 31, 2023 | 6.7730 | -0.3600 | -5.05% | 7.1330 | 8.6430 | 6.6730 |
Helius Medical Technologies, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 13, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2023 Helius Medical Technologies Inc Earnings Release Q3 2023 Helius Medical Technologies Inc Earnings ReleaseForecast -Previous - |
| Thursday, March 7, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Helius Medical Technologies Inc Earnings Release Q4 2023 Helius Medical Technologies Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 0.787 | 0.522 | 0.661 | 1.496 | 0.478 |
| Total Operating Expense | 16.303 | 18.664 | 15.047 | 25.492 | 27.153 |
| Selling/General/Admin. Expenses, Total | 10.64 | 12.158 | 9.404 | 16.521 | 17.214 |
| Research & Development | 4.262 | 5.99 | 4.582 | 8.061 | 9.939 |
| Operating Income | -15.516 | -18.142 | -14.386 | -23.996 | -26.675 |
| Interest Income (Expense), Net Non-Operating | 1.437 | 0.01 | 0.193 | 14.12 | -2.011 |
| Other, Net | 0.007 | 0 | 0.063 | 0.095 | 0.063 |
| Net Income Before Taxes | -14.072 | -18.132 | -14.13 | -9.781 | -28.623 |
| Net Income After Taxes | -14.072 | -18.132 | -14.13 | -9.781 | -28.623 |
| Net Income Before Extra. Items | -14.072 | -18.132 | -14.13 | -9.781 | -28.623 |
| Net Income | -14.072 | -18.132 | -14.13 | -9.781 | -28.623 |
| Income Available to Common Excl. Extra. Items | -14.072 | -18.132 | -14.13 | -9.781 | -28.623 |
| Income Available to Common Incl. Extra. Items | -14.072 | -18.132 | -14.13 | -9.781 | -28.623 |
| Diluted Net Income | -14.072 | -18.132 | -14.13 | -9.781 | -28.623 |
| Diluted Weighted Average Shares | 0.26994 | 0.04914 | 0.02396 | 0.01506 | 0.01302 |
| Diluted EPS Excluding Extraordinary Items | -52.1295 | -369.019 | -589.844 | -649.559 | -2198.38 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -49.3252 | -368.653 | -576.904 | -649.559 | -2198.38 |
| Total Extraordinary Items | |||||
| Revenue | 0.787 | 0.522 | 0.661 | 1.496 | 0.478 |
| Cost of Revenue, Total | 0.463 | 0.298 | 0.388 | 0.846 | 0 |
| Gross Profit | 0.324 | 0.224 | 0.273 | 0.65 | 0.478 |
| Depreciation / Amortization | 0.181 | 0.2 | 0.363 | 0.064 | 0 |
| Dilution Adjustment | 0 | ||||
| Unusual Expense (Income) | 0.757 | 0.018 | 0.31 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Total revenue | 0.282 | 0.196 | 0.119 | 0.19 | 0.258 |
| Revenue | 0.282 | 0.196 | 0.119 | 0.19 | 0.258 |
| Cost of Revenue, Total | 0.15 | 0.101 | 0.088 | 0.124 | 0.129 |
| Gross Profit | 0.132 | 0.095 | 0.031 | 0.066 | 0.129 |
| Total Operating Expense | 2.951 | 5.049 | 3.549 | 4.754 | 4.36 |
| Selling/General/Admin. Expenses, Total | 1.967 | 3.393 | 2.461 | 2.819 | 2.376 |
| Research & Development | 0.794 | 0.751 | 0.953 | 1.764 | 1.808 |
| Depreciation / Amortization | 0.04 | 0.047 | 0.047 | 0.047 | 0.047 |
| Operating Income | -2.669 | -4.853 | -3.43 | -4.564 | -4.102 |
| Interest Income (Expense), Net Non-Operating | -2.223 | 3.823 | -0.38 | 0.217 | 0 |
| Other, Net | 0.006 | 0 | 0 | 0.001 | 0 |
| Net Income Before Taxes | -4.886 | -1.03 | -3.81 | -4.346 | -4.102 |
| Net Income After Taxes | -4.886 | -1.03 | -3.81 | -4.346 | -4.102 |
| Net Income Before Extra. Items | -4.886 | -1.03 | -3.81 | -4.346 | -4.102 |
| Net Income | -4.886 | -1.03 | -3.81 | -4.346 | -4.102 |
| Income Available to Common Excl. Extra. Items | -4.886 | -1.03 | -3.81 | -4.346 | -4.102 |
| Income Available to Common Incl. Extra. Items | -4.886 | -1.03 | -3.81 | -4.346 | -4.102 |
| Diluted Net Income | -4.886 | -1.03 | -3.81 | -4.346 | -4.102 |
| Diluted Weighted Average Shares | 0.56394 | 0.17087 | 0.07857 | 3.78787 | 3.13886 |
| Diluted EPS Excluding Extraordinary Items | -8.66398 | -6.02811 | -48.4893 | -1.14735 | -1.30684 |
| Diluted Normalized EPS | -8.66398 | -1.59774 | -48.4893 | -1.14735 | -1.30684 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Unusual Expense (Income) | 0 | 0.757 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 16.697 | 12.594 | 4.685 | 7.241 | 26.961 |
| Cash and Short Term Investments | 14.549 | 11.005 | 3.331 | 5.459 | 25.583 |
| Cash | 14.549 | 11.005 | 3.331 | 5.459 | 25.583 |
| Total Receivables, Net | 0.343 | 0.251 | 0.23 | 0.574 | 0.275 |
| Accounts Receivable - Trade, Net | 0.071 | 0.066 | 0.074 | 0.21 | 0.275 |
| Prepaid Expenses | 1.216 | 0.862 | 0.735 | 0.61 | 0.447 |
| Total Assets | 17.287 | 14.102 | 6.547 | 10.347 | 27.827 |
| Total Current Liabilities | 1.988 | 2.653 | 2.424 | 3.802 | 17.973 |
| Payable/Accrued | |||||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
| Other Current Liabilities, Total | 0.027 | 0.148 | 0.281 | 0.435 | 13.769 |
| Total Liabilities | 9.136 | 2.846 | 2.676 | 4.512 | 17.973 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | |
| Total Equity | 8.151 | 11.256 | 3.871 | 5.835 | 9.854 |
| Common Stock | 0.028 | 0.004 | 0.001 | 0.031 | 0.026 |
| Additional Paid-In Capital | 159.618 | 149.412 | 123.872 | 111.479 | 105.411 |
| Retained Earnings (Accumulated Deficit) | -151.107 | -137.035 | -118.903 | -104.773 | -94.992 |
| Other Equity, Total | -0.388 | -1.125 | -1.099 | -0.902 | -0.591 |
| Total Liabilities & Shareholders’ Equity | 17.287 | 14.102 | 6.547 | 10.347 | 27.827 |
| Total Common Shares Outstanding | 28.2073 | 3.78067 | 1.48436 | 0.87763 | 0.7379 |
| Property/Plant/Equipment, Total - Net | 0.45 | 0.412 | 0.576 | 1.264 | 0.554 |
| Property/Plant/Equipment, Total - Gross | 0.653 | 0.779 | 1.449 | 0.63 | |
| Accumulated Depreciation, Total | -0.241 | -0.203 | -0.185 | -0.076 | |
| Other Long Term Assets, Total | 0 | 0.018 | 0.018 | ||
| Accounts Payable | 0.627 | 1.069 | 0.747 | 1.676 | 2.392 |
| Accrued Expenses | 1.334 | 1.436 | 1.396 | 1.691 | 1.812 |
| Total Inventory | 0.589 | 0.476 | 0.389 | 0.598 | 0.392 |
| Other Current Assets, Total | 0 | 0.264 | |||
| Note Receivable - Long Term | 0 | 0.294 | |||
| Other Liabilities, Total | 7.148 | 0.193 | 0.252 | 0.71 | 0 |
| Goodwill, Net | 0 | 0.763 | 0.759 | 1.242 | |
| Intangibles, Net | 0.14 | 0.333 | 0.527 | 0.582 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Total Current Assets | 16.697 | 18.217 | 5.064 | 8.026 | 12.594 |
| Cash and Short Term Investments | 14.549 | 16.658 | 3.273 | 6.31 | 11.005 |
| Cash | 14.549 | 16.658 | 3.273 | 6.31 | 11.005 |
| Total Receivables, Net | 0.343 | 0.217 | 0.196 | 0.245 | 0.251 |
| Accounts Receivable - Trade, Net | 0.071 | 0.021 | 0.009 | 0.06 | 0.066 |
| Total Inventory | 0.589 | 0.609 | 0.577 | 0.52 | 0.476 |
| Prepaid Expenses | 1.216 | 0.733 | 0.996 | 0.951 | 0.862 |
| Total Assets | 17.287 | 18.859 | 6.546 | 9.618 | 14.102 |
| Property/Plant/Equipment, Total - Net | 0.45 | 0.464 | 0.493 | 0.52 | 0.412 |
| Goodwill, Net | 0 | 0.753 | 0.777 | 0.763 | |
| Intangibles, Net | 0.14 | 0.178 | 0.236 | 0.291 | 0.333 |
| Other Long Term Assets, Total | 0.004 | ||||
| Total Current Liabilities | 1.988 | 1.2 | 1.777 | 2.199 | 2.653 |
| Accounts Payable | 0.627 | 0.57 | 1.043 | 1.111 | 1.069 |
| Accrued Expenses | 1.334 | 0.604 | 0.706 | 1.059 | 1.436 |
| Other Current Liabilities, Total | 0.027 | 0.026 | 0.028 | 0.029 | 0.148 |
| Total Liabilities | 9.136 | 5.898 | 2.044 | 2.488 | 2.846 |
| Other Liabilities, Total | 7.148 | 4.698 | 0.267 | 0.289 | 0.193 |
| Total Equity | 8.151 | 12.961 | 4.502 | 7.13 | 11.256 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.028 | 0.028 | 0.004 | 0.004 | 0.004 |
| Additional Paid-In Capital | 159.618 | 159.386 | 150.665 | 149.834 | 149.412 |
| Retained Earnings (Accumulated Deficit) | -151.107 | -146.221 | -145.191 | -141.381 | -137.035 |
| Other Equity, Total | -0.388 | -0.232 | -0.976 | -1.327 | -1.125 |
| Total Liabilities & Shareholders’ Equity | 17.287 | 18.859 | 6.546 | 9.618 | 14.102 |
| Total Common Shares Outstanding | 28.2073 | 28.2013 | 4.19511 | 3.7948 | 3.78067 |
| Property/Plant/Equipment, Total - Gross | 0.786 | 0.653 | |||
| Accumulated Depreciation, Total | -0.266 | -0.241 | |||
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
| Total Long Term Debt | 0 | 0 | 0 | 0 | |
| Other Current Assets, Total | 0.022 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -18.132 | -14.13 | -9.781 | -28.623 | |
| Cash From Operating Activities | -13.388 | -11.738 | -20.999 | -19.621 | |
| Non-Cash Items | 4.305 | 2.926 | -9.132 | 9.961 | |
| Changes in Working Capital | 0.127 | -1.016 | -2.277 | -1.018 | |
| Cash From Investing Activities | -0.056 | -0.009 | -0.769 | -0.44 | |
| Other Investing Cash Flow Items, Total | 0 | 0.061 | -0.416 | ||
| Cash From Financing Activities | 21.126 | 9.638 | 1.653 | 40.028 | |
| Financing Cash Flow Items | -2.889 | -1.015 | -0.247 | -3.161 | |
| Issuance (Retirement) of Stock, Net | 24.015 | 10.653 | 1.9 | 43.189 | |
| Foreign Exchange Effects | -0.008 | -0.019 | -0.009 | 0.054 | |
| Net Change in Cash | 7.674 | -2.128 | -20.124 | 20.021 | |
| Cash From Operating Activities | 0.112 | 0.119 | 0.127 | 0.059 | |
| Cash Taxes Paid | 0 | 0 | |||
| Cash Interest Paid | 0 | 0 | |||
| Capital Expenditures | -0.056 | -0.07 | -0.353 | -0.44 | |
| Amortization | 0.2 | 0.363 | 0.064 | ||
| Issuance (Retirement) of Debt, Net | 0 | 0 |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -9.186 | -8.156 | -4.346 | -18.132 | |
| Cash From Operating Activities | -12.167 | -8.346 | -4.682 | -13.388 | |
| Cash From Operating Activities | 0.074 | 0.05 | 0.025 | 0.112 | |
| Amortization | 0.141 | 0.094 | 0.047 | 0.2 | |
| Non-Cash Items | -1.768 | 0.765 | 0.195 | 4.305 | |
| Changes in Working Capital | -1.428 | -1.099 | -0.603 | 0.127 | |
| Cash From Investing Activities | -0.013 | -0.006 | 0.004 | -0.056 | |
| Capital Expenditures | -0.019 | -0.012 | -0.002 | -0.056 | |
| Cash From Financing Activities | 17.869 | 0.62 | -0.017 | 21.126 | |
| Financing Cash Flow Items | -0.775 | -0.024 | -0.017 | -2.889 | |
| Issuance (Retirement) of Stock, Net | 18.644 | 0.644 | 0 | 24.015 | |
| Foreign Exchange Effects | -0.006 | -0.008 | |||
| Net Change in Cash | 5.683 | -7.732 | -4.695 | 7.674 | |
| Other Investing Cash Flow Items, Total | 0.006 | 0.006 | 0.006 | 0 | |
| Issuance (Retirement) of Debt, Net | 0 | ||||
| Cash Interest Paid | 0.927 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Helius Medical Technologies, Inc. Company profile
About Helius Medical Technologies Inc
Helius Medical Technologies, Inc. is a neurotech company focused on neurological wellness. The Company focuses on developing, licensing or acquiring non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The Company's product, Portable Neuromodulation Stimulator (PoNS) is a class II, non-implantable medical device intended for use as a short-term treatment (14 weeks) of gait deficit due to symptoms from multiple sclerosis (MS), and balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with supervised therapeutic exercise (PoNS Treatment). The Company's subsidiaries include Helius Medical, Inc., Helius Medical Technologies (Canada), Inc., Helius NeuroRehab, Inc., Helius Canada Acquisition Ltd. and Heuro Canada, Inc.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Helius Medical Technologies Inc revenues decreased 21% to $522K. Net loss increased 28% to $18.1M. Revenues reflect Product sales decrease of 21% to $493K, Fee revenue decrease from $9K to $0K. Higher net loss reflects General and administrative increase of 25% to $12.2M (expense), Research and development increase of 31% to $6M (expense), Foreign exchange gain decrease of 95% to $10K (income).
| Industry: | Advanced Medical Equipment & Technology (NEC) |
642 Newtown Yardley Road
NEWTOWN
PENNSYLVANIA 18940
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com